ovarian cancer

CDC issues interim guidance on congenital Zika infectionNew interim guidance from The Centers for Disease Control and Prevention (CDC) emphasizes the need for standard screening and monitoring of infants with possible congenital Zika virus infection plus hearing screening and specific testing and evaluation in three clinical scenarios. Plus: Are at-risk women commonly tested for rectal gonorrhea, chlamydia? Also: According to a study, ovarian cancer may originate in fallopian tubes.
$417 Million Award from Lawsuit DroppedA judge tossed an award given to a woman claiming baby powder caused ovarian cancer.
Is genetic testing for cancer survivors underutilized?One study looks at whether or not women with histories of breast or ovarian cancer are receiving necessary genetic testing. Plus: Can in-office hysteroscopy reliably evaluate uterine pathology? Also, researchers say mammographic density changes should be monitored in patients undergoing hormone therapy as a possible indicator of breast cancer.
Health plans explain genetic testing coverage decisions
Health plans explain genetic testing coverage decisionsToday there are nearly 67,000 genetic tests. With so many tests available, it can be difficult for MCOs to determine what to cover.
PARP inhibitor shows promise in ovarian cancerStudy shows Clovis Oncology’s rucaparib shows clinically meaningful impact in delaying disease recurrence in ovarian cancer.
Ovarian cancer: Possible advantage of high blood pressureNew research shows hypertension, diabetes influence survival of ovarian cancer patients in different ways.
IUD blamed for multiple miscarriagesA woman sues her ob/gyn claiming that 3 miscarriages occurred because of an IUD that the ob/gyn believed had been expelled shortly after implantation, but was subsequently found using abdominal x-ray. Plus more cases.
Who is being tested for BRCA?A study looks at who is being tested for BRCA mutations as testing becomes more common. Also, a look at the impact of Zika virus on birth defects using benchmark data. Plus: How is the United States doing with infant mortality?
Advanced ovarian cancer drug approvedFDA recently approved rucaparib (Rubraca, Clovis Oncology) tablets to treat patients with deleterious BRCA mutation (germline and/or somatic)-associated advanced ovarian cancer, who have been treated with 2 or more chemotherapies.
FDA approves expansion of Avastin in ovarian cancerFDA recently approved bevacizumab (Avastin, Genentech) for patients with platinum-sensitive recurrent epithelial ovarian (psOC), fallopian tube or primary peritoneal cancer.